What does 'drug price' even mean?

And who gets to "play god?" 

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT's Sharon Begley joins us to discuss a fascinating debate in genome editing: The scientific establishment says CRISPR'ing embryos is an ethical nonstarter, but patients with serious inherited diseases see things differently. Then, STAT D.C. correspondent Nicholas Florko joins us to break down the murky details of the drug industry's new transparency initiative.

You can listen to the episode here. To listen to future episodes, be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.